Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Aug;27(8):3333-3342.
doi: 10.1007/s00330-016-4702-y. Epub 2016 Dec 21.

Treatment of cerebral vasospasm following aneurysmal subarachnoid haemorrhage: a systematic review and meta-analysis

Grégoire Boulouis  1   2 , Marc Antoine Labeyrie  3   4 , Jean Raymond  5 , Christine Rodriguez-Régent  6   3 , Anne Claire Lukaszewicz  6   3 , Damien Bresson  3   4 , Wagih Ben Hassen  6   3 , Denis Trystram  6   3 , Jean Francois Meder  6   3 , Catherine Oppenheim  6   3 , Olivier Naggara  6   3
Affiliations
Meta-Analysis

Treatment of cerebral vasospasm following aneurysmal subarachnoid haemorrhage: a systematic review and meta-analysis

Grégoire Boulouis et al. Eur Radiol. 2017 Aug.

Abstract

Objectives: To examine the clinical outcome of aneurysmal subarachnoid haemorrhage (aSAH) patients exposed to cerebral vasospasm (CVS)-targeted treatments in a meta-analysis and to evaluate the efficacy of intra-arterial (IA) approaches in patients with severe/refractory vasospasm.

Methods: Randomised controlled trials, prospective and retrospective observational studies reporting clinical outcomes of aSAH patients exposed to CVS targeted treatments, published between 2006-2016 were searched using PubMed, EMBASE and the Cochrane Library. The main endpoint was the proportion of unfavourable outcomes, defined as a modified Rankin score of 3-6 at last follow-up.

Results: Sixty-two studies, including 26 randomised controlled trials, were included (8,976 patients). At last follow-up 2,490 of the 8,976 patients had an unfavourable outcome, including death (random-effect weighted-average, 33.7%; 99% confidence interval [CI], 28.1-39.7%; Q value, 806.0; I 2 = 92.7%). The RR of unfavourable outcome was lower in patients treated with Cilostazol (RR = 0.46; 95% CI, 0.25-0.85; P = 0.001; Q value, 1.5; I 2 = 0); and in refractory CVS patients treated by IA intervention (RR = 0.68; 95% CI, 0.57-0.80; P < 0.0001; number needed to treat with IA intervention, 6.2; 95% CI, 4.3-11.2) when compared with the best available medical treatment.

Conclusions: Endovascular treatment may improve the outcome of patients with severe-refractory vasospasm. Further studies are needed to confirm this result.

Key points: • 33.7% of patients with cerebral Vasospasm following aneurysmal subarachnoid-hemorrhage have an unfavorable outcome. • Refractory vasospasm patients treated using endovascular interventions have lower relative risk of unfavourable outcome. • Subarachnoid haemorrhage patients with severe vasospasm may benefit from endovascular interventions. • The relative risk of unfavourable outcome is lower in patients treated with Cilostazol.

Keywords: Cerebral vasospasm; Delayed cerebral ischaemia; Endovascular treatment; Meta-analysis; Subarachnoid haemorrhage.

PubMed Disclaimer

References

    1. Crit Care Med. 2010 May;38(5):1284-90 - PubMed
    1. Neuroradiology. 2011 Feb;53(2):123-8 - PubMed
    1. AJNR Am J Neuroradiol. 2010 Nov;31(10):1911-6 - PubMed
    1. Stroke. 2008 Jun;39(6):1759-65 - PubMed
    1. J Neurosurg. 1968 Jan;28(1):14-20 - PubMed

MeSH terms

LinkOut - more resources